Massachusetts scientist announces campaign to take on Congressman Jake Auchincloss with platform aimed at Big Pharma

CAMBRIDGE, MA — Republican congressional candidate Tom Stalcup, PhD, will officially launch his campaign for U.S. Congress in Massachusetts’ 4th District this Saturday outside Biogen’s corporate headquarters in Cambridge, MA.

“I’m taking on Big Pharma and their high drug prices because Congressman Jake Auchincloss refuses to. Big Pharma funds his campaigns, and when he talks about the problem, he just repeats their talking points”, says Dr. Tom Stalcup prior to his official launch this weekend.

The announcement will also mark the kickoff of “Stalcup v. Big Pharma,” a campaign initiative focused on exposing pharmaceutical pricing practices and political influence in Washington.

The launch is scheduled for Saturday, April 4, 2026, at 11:00 a.m. on the sidewalk directly in front of Biogen’s corporate headquarters at 225 Binney Street, Cambridge.

Stalcup, a Brookline resident and scientist, is running on a platform of “Science over Politics,” with a central focus on lowering healthcare and prescription drug costs by directly confronting pharmaceutical industry influence.

“There were years I couldn’t afford health insurance at all—even after the Affordable Care Act,” said Stalcup. “Families across this district are being crushed by rising drug prices, and they’re being told it’s someone else’s fault. But the reality is simple: Big Pharma sets the prices.”

Stalcup sharply contrasted his campaign with incumbent Jake Auchincloss, arguing that the current representative has aligned himself with pharmaceutical industry interests. “My opponent takes hundreds of thousands of dollars from Big Pharma, then helps them deflect blame while prices keep rising,” Stalcup said. “That’s not leadership—that’s serving as a shield for the very companies driving the problem.”

The choice of Biogen headquarters as the launch site is intentional. A release noted that the company has faced national scrutiny over drug pricing—most notably with its Alzheimer’s drug Aduhelm, which drew intense criticism from lawmakers, insurers, and physicians for its high cost and uncertain benefit. Its spinal muscular atrophy drug Spinraza has also been cited in broader concerns about the rising cost of specialty medicines.

Stalcup will deliver remarks outlining his plan to lower drug prices, increase transparency, and eliminate what he describes as special-interest protections that allow pharmaceutical companies to maintain high prices with limited accountability.

“‘Stalcup v. Big Pharma’ is about one simple question: who does government work for—patients or pharmaceutical companies?” Stalcup said. “I’m running to make sure it’s patients.”